Novel targeted therapy regimens show promise in aggressive AML subtype
MECOM-rearranged acute myeloid leukemia (AML) is an aggressive and hard-to-treat leukemia
Researchers combined three inhibitors and observed cancer cell death and increased survival in lab models
Researchers at The University of Texas MD Anderson Cancer Center have identified new potential combination therapies to target high-risk MECOM-rearranged acute...
ASH 2025: New data highlights promise of pivekimab sunirine in two aggressive blood cancers
Two clinical studies demonstrate high response rates by patients with two hard-to-treat and aggressive blood cancers
Pivekimab...
ASH 2025: Researchers identify CD40 as potential biomarker for a type of nodal T cell lymphoma
Researchers characterized the microenvironment of a nodal T cell lymphoma that is difficult to diagnose and treat
The study...
ASH 2025: Shorter azacitidine regimen safely improves outcomes in lower-risk MDS patients
Azacitidine is a type of targeted therapy known as a hypomethylating agent, commonly used in treating myelodysplastic syndromes (MDS)
Five-day azacitidine showed superior survival outcomes and disease control in lower-risk MDS patients
All trial regimens evaluated were safe, but the five-day regimen offered the best balance of safety and efficacy
ORLANDO, DECEMBER 7, 2025 – Patients with lower-risk...
ASH 2025: Results show long-lasting benefits of CAR T cell therapy for hard-to-treat lymphoma
Lisocabtagene maraleucel (liso-cel), a CAR T cell therapy, achieved an overall response rate of 97% in the TRANSCEND FL study
Durable...
ASH 2025: New MD Anderson-developed antibody boosts immune response against blood cancers and solid cancers
New investigational therapy 77A is an antibody that converts a cancer survival protein (HSP70) into an immune system trigger
Targeting...
ASH 2025: CAR T cell therapy shows promising Phase II trial results in multiple myeloma
Anito-cel is an experimental CAR T cell therapy for relapsed/refractory multiple myeloma patients
In updated Phase II trial results...
Spatial analysis finds immune-rich pockets in diffuse large B-cell lymphoma tumors with clear treatment potential
Study identified seven distinct and unique microenvironments within diffuse large B-cell lymphoma (DLBCL)
Immune-privileged DLBCLs...
Researchers identify genetic markers that affect treatment outcomes in patients with large B-cell lymphoma
Multiple genetic markers play a key role in the treatment outcomes of patients with large B-cell lymphoma (LBCL) who received chimeric antigen...
Stem cell transplant achieves positive outcomes in second remission for adolescents and young adults with ALL
A new study from The University of Texas MD Anderson Cancer Center and Dana-Farber Cancer Institute, published in American Journal of Hematology...
Patients receiving anti-cancer treatment near end of life experience higher rates of hospitalization, ED and ICU use, and less utilization of hospice
Patients who receive systemic anti-cancer treatment near end of life are more likely to be hospitalized, go to the intensive care unit or...